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Edited by Veli-Pekka LehtoAbstract Although cancer of the prostate (CaP) is the most
commonly occurring cancer in males, there are major limitations
in its diagnosis and long-term cure. Consequently, understanding
the molecular mechanisms involved in the progression of CaP is
of particular importance for production of pharmacological and
biological agents to manage the disease. The development of the
normal prostate is regulated by stromal–epithelial interactions
via endocrine and paracrine factors, such as androgens and
growth factors, which act as precise homeostatic regulators of
cellular proliferation. Importantly, after a period of hormonal
therapy, CaP shifts from an androgen-dependent to an androgen-
independent state with a concomitant switch from paracrine to
autocrine growth factor stimulation and subsequent upregulation
of growth factor expression. Thus, growth factors and their
receptors have a pivotal role in CaP. This is emphasized by
current evidence obtained from clinical specimens as well as
several in vitro and in vivo models strongly suggesting that
epidermal growth factor and the neurotrophins (nerve growth
factor, brain derived neurotrophin factor, neurotrophin-3 and
neurotrophin-4/5) together with their tyrosine kinase receptors
could play a very signiﬁcant role in CaP progression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cancer of the prostate (CaP) is themost commonly diagnosed
cancer in males, aﬄicting one man in nine over the age of 65 [1].
In order to understand the initiation and progression of CaP, it
is necessary ﬁrst to elucidate the molecular mechanisms in-
volved in the development of the normal prostate gland. It is
well established that stromal–epithelial interactions, through
endocrine and paracrine factors, extracellular matrix compo-
nents, cell–cell contact together with locally produced andro-
gens and growth factors, are involved in normal prostate
development and function [2–4]. There is also evidence that
regulation of prostatic growth is maintained by androgen de-
pendent secretion of paracrine growth factors which, during
normal development, behave as mitogens of prostatic epithelial
cells [3,4]. Importantly, this balance is destabilized in CaP and,* Corresponding author. Fax: +44-20-7584-2056.
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netic deregulation of cell growth control can occur due to ac-
quisition of androgen-independent autocrine growth factor
stimulation [3–5]. Such stimulation has been implicated in
tumour growth, angiogenesis and metastasis which, in turn,
involve cellular proliferation, adhesion, secretion and motility
[3–5]. Therefore, analysis of the deregulation of the functional
relationship between growth factors and their receptors is
central to determining the pathogenesis of CaP.
Current knowledge regarding the roles of epidermal growth
factor (EGF) and the neurotrophins – nerve growth factor
(NGF), brain derived nerve growth factor (BDNF), neuro-
trophin-3 (NT-3) and neurotrophin 4/5 (NT-4/5), as well as
their tyrosine kinase receptors – epidermal growth factor re-
ceptor (EGFR) and members of the trk family (trk A, trk b
and trk c) – suggest strongly that these systems have a fun-
damental role in stromal–epithelial interactions during the
initiation and progression of CaP.2. Basic cellular architecture of the human prostatic duct
The basic functional units of the normal adult prostate are
ducts composed of epithelial cells associated with stromal cells.
There are at least three diﬀerent epithelial cell types which have
been characterized by their morphology, functional properties
and possible role in carcinogenesis (Fig. 1). The prevailing
epithelial cell type is the secretory luminal cell [6,7]. These are
diﬀerentiated and androgen-dependent cells able to secrete
proteins such as growth factors. As well as androgen receptors,
these cells express cytokeratins 8 and 18 and the cell surface
marker CD57 [6–8]. The second epithelial cell type is the basal
cell. These cells are located primarily in the underlying base-
ment membrane and form a uniform continuous layer. Some
basal cells may also be present among the luminal cells [6,7,9].
Basal cells, which appear not to be secretory, are characterized
by the expression of CD44, cytokeratins 5, 14 and possible low
levels of androgen receptor [6,7,9]. Interestingly, analysis of the
cytokeratin expression patterns suggested also the presence of
transient populations of cells with basal/luminal properties
that may be stem cells [10,11]. The third type of epithelial cell is
the neuroendocrine cell [12]. These cells are a minor popula-
tion scattered throughout the basal layer and provide para-
crine signals able to support the growth of luminal cells [12,13].
Neuroendocrine cells are androgen-independent but express
chromogranin A and serotonin [12,13]. The stroma is mainly
composed of smooth muscle type cells, associated with ablished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic representation showing a typical normal human
prostate duct. Within the adult duct, the positions of luminal, basal
and neuroendocrine epithelial cells as well as the stroma can be ob-
served. It should be noted that there is no morphological distinction
between epithelial neuroendocrine and basal cells.
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tins), ﬁbroblasts, adipocytes, lymphocytes, endothelial cells,
pericytes and neuromuscular tissue [14–16]. The smooth
muscle cells produce growth factors such as EGF and neuro-
trophins such as NGF [15] and appear to play a signiﬁcant role
in prostate development and maintenance of homeostasis [15].
The current view is that the stroma is characterized by a
constant modulation of diﬀerent and individual cell pheno-
types, which oscillate between those of ﬁbroblastic origin to
those of diﬀerentiated smooth muscle type and most likely
others that still need to be identiﬁed [17].Fig. 2. Schematic representation of human prostate cancer progres-
sion. The integrity of normal adult duct is maintained by its androgen
dependence. Subsequently, with the onset of prostatic intraepithelial
neoplasia (PIN), there is disorganization of luminal and basal epithe-
lial cells. PIN leads to invasive carcinoma and the full disarray of both
luminal and basal cells with concomitant loss of the basal lamina.
Finally, during metastasis there is migration to other body sites of
malignant epithelial cells which, when patients undergo androgen
withdrawal treatment, become androgen independent.3. Prostate cancer and its progression
Fig. 2 illustrates the main stages in the progression of CaP.
Prostatic intraepithelial neoplasia (PIN) has been suggested to
be the precursor of CaP [18,19]. PIN is a continuum from low-
to high-grade lesions conﬁned to the prostatic capsule/duct
[18,19]. PIN can have allelic imbalance as well as architectural
and cytological properties resembling invasive carcinoma, such
as disruption of the basal layer and low levels of expression of
markers (such as matrix metalloproteinase-2 and kallikreins)
associated with early invasive carcinoma [18]. PIN can be
followed by invasive carcinoma, characterized by loss of the
basal lamina, over proliferation of basal and luminal cells and
full expression of matrix metalloproteinase-2 and kallikreins
[20]. Subsequently, invasive carcinoma may progress to a more
aggressive form capable of local invasion of the seminal vesi-
cles [20,21]. Finally, metastasis may occur primarily to bone
and then to lung, and can be lethal. Importantly, in patients
undergoing androgen ablation treatment, the transition from
invasive carcinoma to metastasis is characterized by a shift
from an androgen-dependent to an androgen-independent
state [20,21]. The initial pathology of malignant cell migration
within the prostate is predominantly by direct extension
around prostatic nerves. This invasion, via the micro-lym-
phatic system, follows the course of nerve branches to the
superior pedicle and inferior pedicle where capsule penetration
is most common [20].
It is important to note that CaP rarely arises spontaneously
in animals (with the exception of dog), thus, to investigate the
mechanisms involved in the progression of this type of neo-
plasia, emphasis has been placed on the production of humanxenografts, transgenic and knockout mice as well as model cell
lines. We should strongly emphasize, therefore, that although
it is possible that observations made on given cellular models
may not individually accurately represent human CaP, results
obtained from diﬀerent systems taken together could throw
light on the various clinical aspects of CaP progression.4. Tyrosine kinase receptors and their ligands in CaP
This section describes what is currently known about the
involvement of EGF, neurotrophins and their receptors in the
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mentioned only within the context of the role of EGF). Fun-
damentals of the structure and function mechanisms of these
growth factors and their receptors have been reviewed previ-
ously [22–25].4.1. EGF
In the normal adult prostate, EGF can be detected as a se-
creted protein [5]. ELISA has shown EGF to be present in the
prostatic ﬂuid of adult prostate [26]. Also, immunohisto-
chemical and ELISA analyses of EGF expression in normal
prostate epithelial cells showed that it is produced by luminal
cells, speciﬁcally in the luminal/apical region of these cells, and
released into the lumen of the prostatic duct [27,28]. Interest-
ingly, immunocytochemical and ELISA studies of TGFa have
shown it to be expressed and secreted by smooth muscle cells
of the stroma in normal adult prostate [28–30].
Further analysis of EGF and TGFa expression demon-
strated that normal and low grade PIN as well as localized
carcinomas lack or have very low EGF and TGFa expression
[28–30]. However, poorly diﬀerentiated tumours and highly
metastatic CaP cell lines such as PC-3 and DU-145 were shown
to express detectable levels of EGF and TGFa [30]. These
results taken together give an indication that high amounts of
EGF and TGFa are preferentially expressed in poorly diﬀer-
entiated as well as metastatic tumours but not in localized and
diﬀerentiated carcinomas or normal prostate.Fig. 3. (a) Diagram showing expression of EGF, TGFa and EGFR in
normal and malignant prostate accini. In normal adult prostate, the
secretory luminal epithelial cells are well organized and only separated
by the tight junctions. This allows secretion of EGF into the lumen and
avoids autocrine stimulation of EGF receptors located in the baso-
lateral membranes, below the tight junctions. Thus, EGFR molecules
in this location are only stimulated by TGFa produced by the stroma.
(b) In the neoplastic accini and as the basal and luminal cells become
disorganized, EGFR molecules, located in the basolateral membranes,
become exposed to EGF secreted from the apical membrane, thus
resulting in an autocrine stimulating proliferation loop.4.2. EGFR
Comparative immunohistochemical analysis of EGFR ex-
pression in biopsies of normal prostate, PIN, together with
carcinomas of the prostate with or without severe intraductal
dysplasia showed strong EGFR immunostaining in basal but
not luminal cells of normal prostate, very diﬀuse/weak cyto-
plasmic staining in poorly diﬀerentiated carcinomas and met-
astatic samples as well as a discontinuous basal pattern of
staining in PIN [31–33]. A thorough analysis of PIN demon-
strated that low-grade PIN had strong positive staining
whereas in high-grade PIN levels of staining had only mod-
erate intensity [33]. Furthermore, analysis of EGFR mRNA
expression showed that localized or more diﬀerentiated sam-
ples appeared to express signiﬁcantly more mRNA than nor-
mal prostate epithelium [33]. However, comparable studies of
EGFR mRNA expression of CaP specimens did not ﬁnd a
signiﬁcant diﬀerence in levels or any correlation across various
types or grades; similar results were obtained by immunohis-
tochemical staining of EGFR protein in sections of the same
samples [34,35].
Because of the ambiguity in the results obtained by several
laboratories, a comparative analysis of EGFR was carried out
in foetal, neonatal, pre-pubertal and young adult glands with
PIN and carcinoma [36]. This investigation showed that
EGFR protein is strongly and exclusively expressed in basal
cells of foetal samples [36]. In neonatal and prepubertal glands,
EGFR continued to be present only in basal cells [36]. In
normal adult prostate, detectable EGFR levels were strictly
localized in basal cells and in the lateral plasma membranes of
luminal cells. Irrespective of grade, PIN showed moderate-
diﬀuse staining of EGFR in the majority of luminal cells.
Moderate-diﬀuse staining was also observed in carcinomas
[36].A possible model based on the evidence presented by this
investigation together with what is known, to date, about the
expression of EGF and TGFa is illustrated in Fig. 3. In adult
prostate, this model accounts for the response to stromally
produced TGFa, by EGFR present on the basolateral mem-
brane, below the tight junctions of the luminal cells (Fig. 3(a)).
In this situation, EGFR cannot be accessed by the high levels
of EGF produced by the apical region of the luminal cells but
only the low concentrations of the stromally produced TGFa.
Thus, TGFa acts as a paracrine factor mediating proliferation
by activating receptors located in the luminal cells [34,36].
During tumorigenesis, however, when the epithelial cells be-
come disorganized and the tight junctions are destabilized,
EGF can access the baso-lateral surface and activate EGFR.
Fig. 4. (a) Diagram showing the expression of neurotrophins and their
receptors in normal and malignant prostate accini. In normal adult
prostate, the secretory luminal epithelial cells are well organized and
only separated by the tight junctions. These cells preferentially express
trk A, trk b and p75 and can only be stimulated with stromally pro-
duced NGF and BDNF in a paracrine fashion. (b) In the neoplastic
accini, the luminal cells become disorganized, lose p75 expression and
produce NGF, BDNF and NT-4/5, which are able to stimulate trkA,
trk b and trk c in an autocrine fashion.
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enhances the autonomous progression of cancerous growth of
the prostate [34,36]. Importantly, autocrine stimulation can
lead to gradual androgen-independence and partial indepen-
dence from stromally produced growth factors, which in turn,
could promote a multilayered epithelium with the ability to
metastasize [37,38] (Fig. 3(b)). Since TGFa is present in CaP
tissues, it is possible that TGFa is also an autocrine growth
stimulator of CaP.
Interestingly in foetal tissue, EGFR and TGFa were shown
to be co-expressed in proliferating epithelia at a time when
androgen receptors were absent, suggesting the possibility that
an androgen-independent autocrine intra-epithelial mechanism
may modulate growth and diﬀerentiation of prostatic epithe-
lium also during development [36]. Thus, it appears that an
intra-epithelial autocrine signalling pathway similar to that
found in the developing prostate is recapitulated in neoplasia.
Indeed, a number of developmental genes have been shown to
be re-expressed in cancer and may be termed ‘‘onco-foetal
genes’’ [39].
In summary, the EGF/TGFa/EGFR autocrine loop is in-
volved in early development of the prostate. With further
maturation, the loop increasingly assumes a paracrine char-
acter enabling interactions between smooth muscle of the
stroma and epithelial cells. This is lost during progression to
neoplasia. However, whilst there is considerable support for
the model shown in Fig. 3, further work is required for full
veriﬁcation.
Finally, there is some evidence that in androgen responsive
LNCaP cells, EGF can also activate the androgen receptor to
initiate a signalling cascade [40]. Similarly, recent data dem-
onstrate that EGFR levels can be increased by the addition
of androgens to LNCaP cells [41]. These results suggest that
other possible autocrine loops could also be involved in CaP
progression.
4.3. EGFRvIII
Mutations of EGFR are very common in several human
tumours including CaP [42]. The most common is the type III
mutation (EGFRvIII) which has a deletion in the extracellular
ligand binding domain [43]. EGFRvIII lacks amino acid resi-
dues 6–273 in the extracellular domain, reducing its size from
170 to 145 kD. This deletion promotes a conformational
change similar to the one induced by ligand binding to wild
type EGFR and thus gives rise to a constitutively active re-
ceptor [43,44]. Accordingly, EGFRvIII undergoes self-dimer-
ization which is dependent on core glycosylation [45].
Expression of EGFRvIII appears to increase as CaP pro-
gresses [42]. EGFRvIII mRNA and protein can be detected in
PIN as well as invasive and metastatic CaP but not in normal
prostate; higher levels of expression have been seen in malig-
nant tissue. Interestingly, EGFRvIII appears to be localized in
the cytoplasm and perinuclear areas of epithelial cells [42].
However, the functional consequence(s) and detailed locali-
zation pattern are not known and need to be investigated
further.
4.4. Neurotrophins
Prostate is the most abundant source of NGF outside the
nervous system [46]. NGF and NGF- immunoreactive proteins
secreted by the prostate are able to stimulate prostatic epi-
thelial growth [46,47]. Because of their mitogenic eﬀects onthese cells, the expression and role of neurotrophins have been
analysed extensively in normal and neoplastic prostatic tissue.
Immunocytochemistry of normal prostate and primary carci-
noma samples showed NGF to be localized in the stroma
of normal prostate [47]. Furthermore, a comparative analysis
of mRNA as well as DNA from stromal smooth muscle cells of
normal prostate and non-metastatic LNCaP cells (known to be
growth stimulated by NGF) showed that only smooth muscle
cells expressed mRNA for NGF and BDNF [48] (Fig. 4(a)).
Further analysis showed that NT-3 was not detected in either
smooth muscle or normal epithelial cells, indicating that there
might be other potential sources of NT-3 expression in normal
prostate. Similarly, NT-4/5 did not appear to be expressed in
smooth muscle cells [48].
An investigation to determine whether neurotrophins were
produced by CaP cell lines showed that in the non-metastatic
LNCaP cells, neurotrophin expression was not detected [49].
In contrast, metastatic DU145 and PC-3 cells secreted mea-
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creted NGF was able to induce diﬀerentiation of rat pheo-
chromocytoma PC12 cells [50,51]. PC-3 cells were also
similarly shown to secrete detectable BDNF [50]. These results
suggested that malignancy could involve a switch from para-
crine to autocrine control of neurotrophin activity (Fig. 4(b)).
However, a more thorough investigation using other CaP
models is needed to deﬁne this possibility.4.5. trk(s)
Immunocytochemical analysis of normal prostate and CaP
tissue biopsies showed the expression of members of the trk
family (trk(s)) in epithelial cells of all tissues studied [47]. trk(s)
were found to be localized in the epithelial component of the
ducts, speciﬁcally, in both basal and luminal epithelial cells [47]
(Fig. 4(a)). Further immunocytochemical analysis of normal
and malignant prostate tissues showed that the majority of
normal ductal basal cells expressed trk A and sporadically the
androgen receptor, but not trk b or trk c [52] (Fig. 4(a)).
In order to determine the role of trk(s) in CaP, comparative
mRNA and DNA analyses of stromal smooth muscle cells of
normal prostate and LNCaP cells were performed. These ex-
periments showed that smooth muscle cells expressed mRNA
only for trk c, whereas LNCaP cells expressed all trk(s) [47]
(Fig. 4(b)). A more detailed investigation of the levels of
mRNA transcripts for each individual trk member in LNCaP
cells found that trk c was highly expressed when compared to
trk A and trk b [52]. Thus, it is possible, as in the case of EGF,
TGFa and EGFR, that trk(s) and neurotrophin expression in
normal prostate is involved in paracrine mechanisms in such a
way that NGF and BDNF produced by the stromal smooth
muscle cells are able to stimulate trk A and probably trk b
when expressed by the epithelial cells (Fig. 4(a)). As CaP
progresses, however, NGF, BDNF and NT-4/5 produced by
epithelial cells are able to stimulate trk family members, also
expressed by epithelial cells, in an autocrine fashion (Fig. 4(b)).
A recent immunohistochemical analysis of specimens ob-
tained from hormone-treated and non-treated patients showed
that both normal and malignant prostatic epithelial cells were
able to express all neurotrophins and their receptors. In nor-
mal tissue, neurotrophins were observed in luminal secretory
cells, whereas trk(s) were present in basal cells [53]. In this
investigation, NGF was not detected in stromal cells, sug-
gesting that the stroma might not necessarily be a source of
neurotrophins and that instead, neurotrophin paracrine stim-
ulation was provided by luminal cells [53]. These results can
only be treated as preliminary, since they involved only im-
munocytochemical detection and although they are indicative
of an alternative model of paracrine stimulation, further ex-
periments are needed to fully verify their validity.
The combined role of neurotrophins and trk(s) in CaP has
been assessed by a comparative in vitro analysis of the invasive
capacity of LNCaP, PC-3 and DU145 cell lines; results showed
that NGF enhanced the invasiveness of these cell lines in
Matrigel [49,50]. The eﬀects of NGF as well as NT-4/5 in-
volved time- and dose-dependent expression of heparanase (a
heparan sulfate-speciﬁc endo b-D-glucuronidase), which is an
important molecular determinant of metastasis [54]. Also, ex-
posure of LNCaP cells to NGF increased their proliferation
and the mitogenic action of NGF appeared to be mediated by
trk A. Overall, these data suggested that activation of trk(s) bytheir ligands could lead to proliferation and metastatic pro-
gression of CaP.
In summary, autocrine expression and activity of neurotro-
phins in prostate may enhance extracapsular invasion and
migration of metastatic cells along the microlymphatic system.
Once outside the prostate, autocrine neurotrophin expression
may provide a suﬃcient source of these factors to maintain the
viability and proliferative capacity of the trk(s)-expressing tu-
mour cells during metastasis to distant sites.
4.6. p75
The role of the low-aﬃnity NGF receptor p75 (a member of
the tumour necrosis family [24,25]) has also been assessed in
normal and neoplastic prostate. p75 has been detected only in
normal tissue and found to be localized unevenly in the epi-
thelial component of the ducts [47]. Immunocytochemistry of
normal and primary carcinoma samples also showed that the
majority of normal ductal basal cells expressed p75 [55]. In-
terestingly, luminal cells of normal prostate expressed trk A
and p75; however, when compared to the expression in basal
cells, trk A was detected at higher levels than p75 [55]
(Fig. 4(a)). In all cases, p75 was not detected in primary car-
cinomas [47,52]. In order to determine the stage at which the
expression of p75 is lost during CaP progression, the presence
of p75 was evaluated in PIN and malignant tissues categorized
into well, moderately and poorly diﬀerentiated primary carci-
nomas [55]. It was found that p75 was present in PIN and loss
of p75 was directly related to the grade of malignancy with
poorly diﬀerentiated carcinomas having undetectable p75 [54].
This change was also seen in vitro, analysis of normal prostate
epithelia showed expression of trk(s) and p75 [56], whereas p75
was not detected in DU-145, PC-3 and LNCaP cell lines
[48,57].
To elucidate the function of p75, LNCaP cells, which do not
express p75, were stably transfected with this receptor. Ex-
pression of p75 decreased the dose dependent stimulation of
proliferation by NGF [58]. NGF deprivation and treatment
with anti-NGF antibodies signiﬁcantly increased the propor-
tion of epithelial cells undergoing apoptosis, whereas addition
of NGF rescued cells from programmed cell death [58]. These
results would suggest that p75 is a negative modulator of ep-
ithelial cell growth by inducing apoptosis. Hence, loss of p75
appears to contribute to malignancy by promoting prolifera-
tion and suppression of growth inhibitory pathway(s) [48,59].
The role of p75 in relation to trk(s) has also been assessed.
Analysis of trk(s) stimulation in diﬀerent cell lines showed that
BDNF was not directly involved in receptor activation [47].
However, since binding of neurotrophins to p75 would inhibit
cell death, it is very likely that BDNF binding to p75 could
induce survival of epithelial cells and NGF binding to trk A
induced proliferation, resulting in the overall stimulation of
growth [47]. These ﬁndings have been supported by mRNA
analysis of DU145 and PC-3 cells showing high levels of NGF
and BDNF transcripts [48]. In conclusion, in normal prostate
and CaP, autocrine NGF may only interact with trk A, au-
tocrine NT-4/5 with both trk b and trk A, while BDNF may
only stimulate p75.
In order to ascertain whether the absence of p75 expression
in CaP is due to full or partial deletion of the p75 gene, DNA
from DU145, PC-3 and LNCaP cells was analysed and it was
found that lack of p75 expression was not due to deletion [60].
Furthermore, reverse transcription polymerase chain reaction,
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showed detectable transcription of p75 [60]. Transient trans-
fection with the 30 end untranslated region of p75 (a region
involved in mRNA stabilization by cytosolic factors able to
interact with elements in this region) did not promote the ex-
pression of p75 protein, thereby suggesting that speciﬁc cyto-
solic factors could be lost during CaP progression thus leading
to mRNA instability and loss of p75 expression [60].4.7. Neurotrophin precursors
There is evidence that neurotrophins are synthesized as
precursors that are proteolytically cleaved to biologically ac-
tive neurotrophins [46,48,61]. The NGF precursor is proteo-
lytically cleaved at amino acids )71 to )43 and )40 to )3.
Analyses of these products have been carried out using speciﬁc
antibodies, which revealed that mature NGF was not ex-
pressed by stromal cells of normal prostate; instead, two pre-
cursors (35 and 27 kD) together with a partially processed 22
kD form were detected [48]. To determine whether mature or
cleaved NGF products were able to activate trk A in malignant
cells, the eﬀects of the precursors together with mature NGF
were tested on B5 cells (a derivative cell line from DU145
cells) and were shown to stimulate receptor phosphorylation/
activation [61]. Importantly, a more recent study showed
that NGF precursors can activate p75 and induce apoptosis
without stimulating trk A [62]. These results raise the possi-
bility that the role of NGF precursors is to activate p75 and
to maintain optimal cell numbers during normal prostate
development.5. Pharmacological and clinical aspects
Because of the potential role of growth factors in CaP,
several types of pharmacological and biological agents have
been produced to target EGFR and members of the trk family.
The most promising class of compounds that block EGFR are
small-molecule inhibitors of its kinase activity [63,64]. These
belong to the aniliquinazolines and act by competitively
binding and inhibiting the ATP binding domain [63,65].
Clinically, the most advanced analogue is ZD-1839, which has
several eﬀects on EGFR-expressing cells such as induction of
cell arrest, increasing apoptosis and reduction of proliferation
[63,65]. Animal models treated orally with ZD-1839 showed
signiﬁcant anti-tumour eﬀects, which could be additive or su-
pra-additive when administered in combination with cytotoxic
compounds such as topoisomerase II inhibitors and anti-me-
tabolites [63,65].
Another approach used to block the activity of EGFR is use
of monoclonal antibodies [66,67]. The antibodies compete for
the ligand binding domain and thus inhibit receptor activity.
Clinically, the most advanced antibody is IMC-225 [67]. This is
a chimera generated by attaching the Fv (variable) regions of
the original anti-EGFR murine monoclonal antibody to a
human IgG1 constant region. This antibody induces apoptosis
and inhibits proliferation, angiogenesis, invasion/metastasis
and cell proliferation after chemotherapy or radiation of tu-
mour cells [67]. Clinical trials of breast carcinoma using IMC-
255 in combination with cytotoxic drugs such as cysplatin have
provided patients with a stable non-progressive disease [66,67].
Combination trials for CaP have not yet been reported.Ribozymes, which are RNA molecules capable of site spe-
ciﬁc cleavage of transcripts with the overall eﬀect of reducing
or blocking protein translation, have been tested as possible
speciﬁc agents against EGFRvIII [68]. EGFRvIII-speciﬁc ri-
bozymes have been found to decrease tumour growth by re-
ducing proliferation of EGFRvIII-expressing cells as well as
decreasing colony formation in soft agar assays [68]. Ribo-
zymes have not yet been tested clinically against CaP.
As in the case of EGF/EGFR, it has become clear that there
is a need to expand the pharmacology that could ablate neu-
rotrophin stimulation of members of the trk family to suppress
CaP progression. The indolocarbazole K252a is a well known
inhibitor of trk kinase [64,69–71] and its analogue CEP-751
has potent anti-tumourigenic activity [71]. CEP-751 selectively
inhibits CaP growth in tumour assays when using human and
rat prostate carcinoma cell lines injected into Copenhagen rats
[69,70]. The anti-tumour eﬀects were independent of androgen
sensitivity, tumour growth rate or metastatic ability [69,70].
Further analysis of the eﬀects of CEP-751 by itself or when
combined with androgen ablation produced transient tumour
regression, independent of the eﬀects on the cell cycle, in the
Dunning R-3327 H rat CaP model [71]. Castration alone in-
duced tumour regression, which was followed by re-growth
after 4–6 weeks, whereas castration together with intermittent
CEP-751 treatment resulted in prolonged tumour regression.
Similar results were obtained when CEP-701 (an analogue of
CEP-751) was administered orally together with a gonado-
trophin-releasing hormone agonist, Leuprolide, to induce an-
drogen ablation [71]. These results indicated that treatment
with CEP-751 or CEP-701 combined with either surgical or
chemical androgen ablation could reduce tumour burden more
eﬃciently than either surgical removal or chemical ablation
alone, and further suggested that these combined therapies
could induce CaP cell death [69,70]. Importantly, eﬀective
doses of these pan-trk inhibitors did not appear to block trk
signalling in epithelial cells or to induce death or proliferation
of normal basal and luminal cells [71].6. A possible association of EGF and NGF with voltage-gated
Na+ channel expression in CaP
A novel approach to understanding the pathophysiology of
CaP suggested that upregulation of voltage-gated Naþ chan-
nels (VGSCs) could be an accelerating factor in CaP metastasis
[72]. This notion emerged from two sets of ﬁndings. First,
whole-cell patch clamp recordings showed consistently that
VGSCs occur only in strongly metastatic CaP cells of both rat
and human [73,74]. Second, blockage of VGSC activity using
the highly speciﬁc neurotoxin, tetrodotoxin, suppressed Ma-
trigel invasion by some 50% [73,74]. VGSC activity also po-
tentiated CaP cells endocytic membrane activity, consistent
with a role in control of secretion [75]. Furthermore, a positive
correlation was found between invasiveness and VGSC ex-
pression in numerous rat and human CaP cell lines [76]. The
concept to emerge from this work is that functional VGSC
expression potentiates a number of cellular behaviours integral
to the metastatic cascade and thus accelerates metastatic dis-
ease. If so, VGSC expression could be a signiﬁcant factor in
diﬀerentiating ‘slow’ from ‘fast’ progressing cancers of the
prostate and could enable potentially metastatic CaP to be
detected whilst still conﬁned to the gland.
X. Montano, M.B.A. Djamgoz / FEBS Letters 571 (2004) 1–8 7Although the mechanism(s) responsible for the VGSC up-
regulation is not known at present, both NGF and EGF are
candidates. Accordingly, application of NGF to PC12 cells
signiﬁcantly increased the expression of the Nav 1.7 (PN1)
subtype of VGSC [77]. Interestingly, this is the predominant
VGSC subtype found in metastatic CaP cell lines of both rat
and human [78]. Also, BDNF has most recently been shown to
be involved in ligand mediated Nav 1.9 activation via trk b
[79]. Importantly, EGF has also been shown to increase VGSC
activity in PC12 cells [77], GH3 cells [80] and rat CaP MAT-
LyLu cells (Ding et al., manuscript in preparation). An in-
triguing possibility, therefore, is whether a positive feedback
between growth factor (GF) release and VGSC upregulation
could occur in CaP progression, as follows:
VGSC expression! VGSC upregulation! GF release
! VGSC upregulation! CaP progression
Such a scheme, operating in either paracrine or autocrine
mode, could be a signiﬁcant ‘self-potentiating’, thus acceler-
ating factor in CaP. Further work is required to test this
scheme and elucidate its potential relevance to metastasis.7. Conclusion
In conclusion, EGF and neurotrophins have potent eﬀects
on CaP progression, especially in conditions when it becomes
androgen refractory. Thus, EGF, neurotrophins, and their
receptors are viable new targets for treating metastatic CaP.
However, more work remains to be done in order to fully
elucidate their mode of action and mechanisms of involvement
in CaP as well as to exploit their clinical potential.References
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